Bristol Myers Squibb
Bristol Myers Squibb has 3 source-linked AI deployments documented in AIUseCaseHub, across 2 industries and 2 countries. Key partners include BenevolentAI, Exscientia, Insilico Medicine.
Hyperscaler mix
See whether Bristol Myers Squibb's cases are powered by Microsoft, AWS, GCP, or multiple providers.
How Bristol Myers Squibb builds AI
Build / Buy / Compose across this company's documented cases
2 of 3 cases classified (67%) · Compare all use-case types
Evidence persistence
2 of 2 judgeable cases are still publicly referenced · 2 show the organization expanding AI use.
Durability of public evidence, not whether systems remain in production. How this is measured →
Technology snapshot
What Bristol Myers Squibb uses across visible cases
AI Agents appears in 1 of 3 indexed cases; 10 named technologies are mentioned, led by Azure OpenAI.
All Use Cases (3)
Enterprises Accelerate Business Process Automation with Azure AI Agent Service
Enterprises such as Bristol Myers Squibb and Core42 are leveraging Azure AI Agent Service to automate complex, manual workflows and achieve scalable, secure AI-driven process automation.Azure AI Agent Service brings unified access to models, tools, services, and enterprise connectors, allowing rapid development and deployment of autonomous agents.Customers use these agentic solutions to automate and personalize tasks like sales operations, report generation, customer follow-up, and developer assistance with deep enterprise integration.The service integrates Azure OpenAI, Azure AI Foundry, Azure Logic Apps, Azure Functions, Microsoft Entra ID, and OpenTelemetry for comprehensive agent deployment and management.Enterprises report accelerated AI adoption, improvements in task efficiency and quality, and robust security and monitoring.The platform supports multi-agent systems and orchestrates actions across diverse data sources and applications, enabling flexible high-performance automation.
Bristol Myers Squibb enhances clinical research and productivity with AI-powered document review
Bristol Myers Squibb (BMS), a leading pharmaceutical company, implemented an internal generative AI solution using Azure OpenAI Service on Microsoft Azure to address the company's intensive document review and research challenges.Led by Chief Digital & Technology Officer Greg Meyers, BMS developed an internal ChatGPT-powered platform tailored for clinical trial documentation, narrative generation, and computational pharmacology.The system enabled tens of thousands of documents to be queried quickly and accurately, transforming long manual review processes into near real-time insights.Generative AI was also used to convert tabular clinical trial data into text narratives, with human oversight ensuring data reliability.Additionally, BMS deployed the solution internally to maintain data privacy and avoid risks associated with public LLMs, leveraging secure agreements with Microsoft Azure.The AI-driven processes extended into protein sequence research, drug discovery, and code debugging, improving insight generation and developer productivity across the organization.BMS established strong AI governance frameworks, responsible AI guidelines, and collaborative communities (AI Collective) to ensure responsible use, bias checks, and regulatory compliance.The initiative created a secure environment for company-wide experimentation, boosting both speed and efficiency in pharma research and operations.
Pharma Investment in AI for Drug Discovery
Pharma companies are increasingly investing in AI to enhance computer-aided drug design (CADD) and reduce drug development time and costs, creating a multibillion-dollar market. Fi...